Strategic partnerships Lumendi holds a worldwide exclusive license to MINT-derived IP and collaborates with Weill Cornell Medical College and New York-Presbyterian Hospital, presenting a compelling case for channel partners seeking licensed, ready-to-market endoluminal solutions in GI procedures.

Expansion potential Recent distribution and partnership announcements in the UK and Ireland with MICRO-TECH Endoscopy, plus ongoing events and workshops, indicate readiness to scale sales through regional distributors and clinical evangelists.

Clinical impact DiLumen and EZ Glide aim to reduce procedure time and invasiveness, offering a differentiator for hospitals pursuing minimally invasive GI interventions and potential cost savings—a strong value proposition for procurement teams.

Market timing Publicized activity at major conferences and endoscopy workshops suggests increasing clinician interest in endoluminal platforms, signaling opportunities to target hospitals, surgery centers, and ambulatory surgery networks ahead of broader adoption.

Financial readiness With revenue in the low-to-mid single-digit millions and partnerships expanding distribution, Lumendi appears positioned for growth investments and ROI-focused conversations with large medical device distributors and hospital systems.